Ketamine Could Treat This Rare Neurological Condition, Says PharmaTher

This article by Emily Jarvie was originally published on Psychedelic Spotlight, and appears here with permission.

The company is also exploring if ketamine can treat other neurological conditions, including Parkinson’s Disease, ALS, and CRPS.

Psychedelic biotechnology company PharmaTher (OTC: PHRRF) believes ketamine could treat yet another rare neurological condition — Status Epilepticus (SE).

The company has applied to the United States Food and Drug Administration (FDA) to receive orphan drug designation for ketamine to treat this condition.

Orphan drug designation is granted to drugs or biological products that show the potential to treat a rare disease, defined by the as conditions that affect fewer than 200,000 people in the United States at any given time. This status provides various benefits and incentives to companies — such as market exclusivity, possible tax credits, and the waiver of the FDA New Drug Application filing fee, which usually costs about $2.4 million — to encourage the development of products to treat these …

Full story available on Benzinga.com

More Ketamine Could Treat This Rare Neurological Condition, Says PharmaTher